Advertisement

Topics

ICON Announces Agreement with Intel Allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials

07:28 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed on preliminary deal terms with Intel Co...

Other Sources for this Article

For ICON
Weber Shandwick
Olivia Pimenta
+44 (0)207 067 0557
OPimenta@webershandwick.com

NEXT ARTICLE

More From BioPortfolio on "ICON Announces Agreement with Intel Allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...